Commentary on the Publication trend of COVID-19 and non-COVID-19 articles in the Indian Journal of Ophthalmology during COVID-19 pandemic.This article analyzes the trend of coronavirus disease 2019 (COVID-19) and non-COVID-19-related papers published in the Indian Journal of Ophthalmology (IJO) during the recent and ongoing pandemic.[1] The authors did a retrospective analysis of all the articles published in IJO between January 2020 and March 2021. Although the articles specifically related to COVID-19 did not form the bulk (13.55%), IJO did show a rising trend in the number of submitted and published papers compared with the previous year. Although this will have a positive impact on the citations and impact factor of our journal, what needs to be seen is whether the trend will continue once the pandemic hopefully ends. The lockdown announced early in 2020 due to increasing COVID-19 cases gave scientists and clinicians across the globe unexpected free time from clinical duties to complete their pending or preexisting work and expedite new research. This led to an obvious surge in the number of articles published across all specialties, more so during the early months of the pandemic. Within the first 3 months itself, there were 215 articles that focused on ophthalmology published in PubMed.[2] There was a significant difference in the contributions based on the geographical location and pandemic severity. The higher impact factor articles were on protective measures, immunology, and clinical manifestations of COVID-19, with the United States, China, Italy, and the United Kingdom publishing the most.[3] Several countries also increased their international scientific collaboration and open-access publications, for both COVID- and non-COVID-related research.[4]Although the rapidity of the data reported and published is not surprising given the circumstances, is the research reliable, will it sustain, and for how long? A meta-research and critical appraisal on COVID-19 papers have shown that most publications were without original data. Interestingly, there was a high risk of bias even for original articles, many of which had very few patients in the study.[5] Another study found that the quality of COVID-19 publications even in high-ranked medical journals was below the average quality.[6] The impact factor for several of these publications has also declined over time.[3] It is important to note that when compared to papers related to previous viral epidemics or pandemics, the retraction record appearance rate for COVID-19-related research is exceptionally high and surpasses the basal level of about 4 in 10,000 papers.[7] These findings suggest that we need to consider the available data with caution given the rapidity with which some of these papers were published.[5]Coming to the sustainability of research being published, a decline in COVID-19-related paper, from close to 140 papers a day since February 2020, is possible as the pandemic abates.[7] We can, however, expect a rise in publications on the research related to different vaccines, the response to the vaccine in different population groups, adverse or usual effects of the vaccines, and long-term repercussion of the pandemic globally. Time will tell if “pandemic publishing” will continue or if the trend will correct itself as clinical work returns to pre-COVID workflows.[89]